(2021). Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease. Stem Cells Translational Medicine.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Phase IV Postmarketing Surveillance Study Shows Continued Efficacy and Safety of Stempeucel in Patients with Critical Limb Ischemia Due to Buerger's Disease."
Stem Cells Translational Medicine 2021.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Phase IV Postmarketing Surveillance Study Shows Continued Efficacy and Safety of Stempeucel in Patients with Critical Limb Ischemia Due to Buerger's Disease."
Stem Cells Translational Medicine, 2021.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.